BioCentury
ARTICLE | Clinical News

4SC-202: Phase I started

April 18, 2011 7:00 AM UTC

4SC began the open-label, dose-escalation, German Phase I TOPAS trial to evaluate 25-400 mg oral 4SC-202 for 14 days in 21-day cycles in up to 36 patients. ...